NWBO Reports $26.8M Q3 Loss, $200K Revenue

Northwest Biotherapeutics, a cancer drug developer, reported a significant loss of $26.8 million in Q3, with a loss per share of $18.22. Despite this, the company generated $200,000 in revenue, offering a glimpse into its operational activity. These financial disclosures provide transparency to investors and highlight the financial challenges faced by biotech companies in the research and development phase.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.